Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement

Hannes Hagström, Leon A. Adams, Alina M. Allen, Christopher D. Byrne, Yoosoo Chang, Henning Grønbæk, Mona Ismail, Peter Jepsen, Fasiha Kanwal, Jeffrey V. Lazarus, Michelle T. Long, Rohit Loomba, Philip N. Newsome, Ian A. Rowe, Seungho Ryu, Jörn M. Schattenberg, Marina Serper, Nick Sheron, Tracey G. Simon, Elliot B. Tapper, Sarah Wild, Vincent Wai-Sun Wong, Yusuf Yilmaz, Shira Zelber-Sagi, and Fredrik Åberg

BACKGROUND AND AIMS: Electronic health record (EHR)-based research allows the capture of large amounts of data, which is necessary in NAFLD, where the risk of clinical liver outcomes is generally low. The lack of consensus on which International Classification of Diseases (ICD) codes should be used as exposures and outcomes limits comparability and generalizability of results across studies. We aimed to establish consensus among a panel of experts on ICD codes that could become the reference standard and provide guidance around common methodological issues.

APPROACH AND RESULTS: Researchers with an interest in EHR-based NAFLD research were invited to collectively define which administrative codes are most appropriate for documenting exposures and outcomes. We used a modified Delphi approach to reach consensus on several commonly encountered methodological challenges in the field. After two rounds of revision, a high level of agreement (>67%) was reached on all items considered. Full consensus was achieved on a comprehensive list of administrative codes to be considered for inclusion and exclusion criteria in defining exposures and outcomes in EHR-based NAFLD research. We also provide suggestions on how to approach commonly encountered methodological issues and identify areas for future research.

CONCLUSIONS: This expert panel consensus statement can help harmonize and improve generalizability of EHR-based NAFLD research. (Hepatology 2021;74:474-482).

Research using routinely collected data from registries on electronic health care records (EHR) is becoming increasingly common with the ongoing digitalization of health care and can make valuable contributions to many fields. (1) For instance, EHR-based research generally enables the inclusion of a vast number of study participants from multiple sites and, depending on the setting, allows for prospective long-term follow-up or historical cohort data. In NAFLD, there are many examples of EHR-based studies that have provided important insight into the natural history of the disease (2-7) and have helped inform international guidelines. (8,9) This type of research can also be used to identify patients with liver diseases not traditionally seen at hepatology clinics, such as patients with NAFLD seen in primary care or by other hospital-based specialists including...

---

**Abbreviations:** ALD, alcohol-associated liver disease; HER, electronic health care records; ICD, International Classification of Diseases; LT, liver transplantation; PPV, positive predictive value.

Received November 13, 2020; accepted January 15, 2021.

Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.31726/suppinfo.

R.L. receives funding support from NIEHS (5P42ES010337), NCATS (5UL1TR001442), NIDDK (U01DK061734, R01DK106419, P30DK120515, R01DK121378, and R01DK124318), NHLBI (P01HL147835), and DOD PPRCP (W81XWH-18-2-0026). A.A. receives funding support from NIH (DK115594).

© 2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
endocrinologists and cardiologists.\(^{10-14}\) In addition, population-based health examination studies, which fall under EHR-based research, allow for the identification of persons in the general population who may be unaware of their disease status.\(^{15-17}\) Furthermore, EHR-based studies could be used to assess the safety and real-world effectiveness of NAFLD drug therapies on patient outcomes outside of clinical trial settings.

However, little effort has been made to standardize the definitions of exposures and outcomes in EHR-based NAFLD research, resulting in many different

**ARTICLE INFORMATION:**

From the 1Division of Hepatology, Department of Upper GI, Karolinska University Hospital, Stockholm, Sweden; 2Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden; 3Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden; 4Medical School, University of Western Australia, Perth, WA, Australia; 5Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN; 6Nutrition and Metabolism, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; 7Southampton National Institute for Health Research Biomedical Research Centre, University Hospital Southampton, Southampton General Hospital, Southampton, United Kingdom; 8Center for Cohort Studies, Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; 9Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark; 10Division of Gastroenterology, Department of Internal Medicine, King Fahad Hospital of the University, Al-Khobar, Saudi Arabia; 11College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; 12Baylor College of Medicine and Michael E. DeBakey VA Medical Center, Houston, TX; 13Barcelona Institute for Global Health (ISGlobal), Hospital Clinic, University of Barcelona, Barcelona, Spain; 14Department of Medicine, Section of Gastroenterology, Boston University School of Medicine, Boston, MA; 15NAFLD Research Center, Division of Gastroenterology and Epidemiology, University of California at San Diego, La Jolla, CA; 16National Institute for Health Research Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust, University of Birmingham, Birmingham, United Kingdom; 17Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom; 18Leeds Institute for Medical Research, University of Leeds, Leeds, United Kingdom; 19Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea; 20Metabolic Liver Research Program, I. Department of Medicine, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; 21Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; 22Foundation for Liver Research, London, United Kingdom; 23Division of Gastroenterology and Hepatology, Massachusetts General Hospital, Boston, MA; 24Harvard Medical School, Boston, MA; 25Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI; 26Inpher, Inc., Minneapolis, MN; 27Pfizer, Inc., New York, NY; 28ProSciento, Sagmet Biosciences, TARGET PharmaSolutions, and Terns. He is on the speakers’ bureau for Bristol-Myers Squibb. Dr. Yilmaz is on the speakers’ bureau for Gilead. He consults for, advises for, and received grants from Biocodex.

DOI 10.1002/hep.31726

Potential conflict of interest: Dr. Kanwal received grants from Gilead and Merck. Dr. Hagstrom consults for and received grants from Gilead. He advises for Bristol-Myers Squibb and received grants from Intercept. Dr. Lataruus consults for Intercept and received grants from Gilead and MSD. Dr. Long received grants from Gilead and Echosens. Dr. Leomba consults for and received grants from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Galmed, Gilead, Intercept, Janssen, Madrigal, NGM, and Pfizer. He consults for Anytime/Regeneron, Amgen, Aradus, CohBar, Glyphx, Inipharm, Ionis, Metacrine, Novartis, Novo Nordisk, Saggmet, 89 Bio, and Viking. He received grants from Allergan, Boehringer Ingelheim, Galetcin, Genfit, Inventivia, Merck, and Siemens. Dr. Rweza advises for Roche and received grants from AbbVie. Dr. Schattenberg consults for, advises for, and is on the speakers’ bureau for Gilead. He consults for and advises for Boehringer Ingelheim, Bristol-Myers Squibb, Echosens, Genfit, Intercept, IQVIA, Madrigal, Nordic Bioscience, Novartis, Novo Nordisk, Pfizer, Siemens, and Healthineers. He is on the speakers’ bureau for Falk Foundation, MSD, and GmüH. Dr. Serper consults for Gilead. Dr. Simon consults for Action and received grants from Amgen. Dr. Tapper consults for and advises for Novo Nordisk. Dr. Wild advises for Gilead. Dr. Wong consults for, advises for, is on the speakers’ bureau for AbbVie and Echosens. He consults for and advises for 3V-BIO, Allergan, Boehringer Ingelheim, Center for Outcomes Research in Liver Diseases, Hanmi Pharmaceutical, Intercept, Merck, Novartis, Novo Nordisk, Persp ectum Diagnostics, Pfizer, ProSciento, Sagmet Biosciences, TARGET PharmaSolutions, and Terrn. He is on the speakers’ bureau for Bristol-Myers Squibb. Dr. Yilmaz is on the speakers’ bureau for and received grants from Gilead. He is on the speakers’ bureau for Echosens and received grants from Biocodex.
definitions being used by distinct research groups. For instance, no clear guidance exists on how to define the progression of NAFLD to cirrhosis, (i.e., which administrative codes to use), or how to define NASH, and current guidelines do not list suggestions for coding. The lack of consensus on definitions threatens the comparability and generalizability of results from different studies. Several methodological considerations, such as how to deal with the risk of misclassification between NAFLD and alcohol-associated liver disease (ALD), are also dealt with differently by distinct research groups. Importantly, few validation studies have been performed to assess the validity of International Classification of Diseases (ICD) codes representative of NAFLD/NASH, whereas codes associated with cirrhosis and HCC have been validated in different settings.

The aim of this study was to survey researchers, including those engaged in EHR-based research, to understand their views regarding the definitions used to document exposures and outcomes in EHR-based NAFLD research with a focus on liver-related outcomes and establish a consensus on which codes are most appropriate to use. We chose to focus on diagnostic coding, given that many databases do not routinely record data on more detailed parameters such as laboratory data. We have also made some general methodological recommendations for future EHR-based studies in this field.

Materials and Methods

A group of researchers with expertise in large-scale database studies in the NAFLD field were invited to collaborate. Initial collaborators were then asked to suggest other key researchers to establish a large panel from diverse countries and settings. All invited collaborators that accepted the invitation were asked to supply feedback on an Excel spreadsheet with diagnostic codes relevant to exposures and outcomes in NAFLD research (Table 1). Administrative codes were defined as codes representing the different stages of NAFLD, including NASH, fibrosis without cirrhosis, compensated cirrhosis, decompensated cirrhosis, HCC, liver transplantation (LT), and a list of important specific liver diseases other than NAFLD relevant to the studies in this field. We defined all diagnoses using ICD coding, versions 8-11. Outdated versions of ICD (version 8 and for some countries version 9) were also included given that retrospective studies using historical data might benefit from using such versions, and the upcoming ICD-11 version was used because it is likely to replace older versions in the coming years (available at: www.who.int/classifications/icd/en/). Additional information sources, such as data on procedure codes and coding for specific pharmacotherapies, were also considered.

An online survey, using the platform www.sogosurvey.com, was used to ask methodological questions. After all collaborators had given feedback, answers were collated and anonymized and results were shared using a modified Delphi approach. Next, an updated spreadsheet was distributed for additional feedback and the survey was redistributed, giving participants an option to change their replies after feedback from the group. Adding additional questions to the survey could be requested by any collaborator. In the end, the questions were defined as statements that generally could be answered with a “yes” or “no” answer. Consensus was defined as >67% agreement with a statement. We highlight statements where consensus was between 67% and 90%, given that these might be topics for future studies.

ETHICAL CONSIDERATIONS

No patient-level data were included in this study; thus, no ethical approval was required.

Results

A total of 27 collaborators were invited, of which 25 (93%) agreed to collaborate, while one did not reply, and one declined to participate. Ninety percent of participants reported using primarily ICD-10 codes, whereas the remainder reported using the ICD-9 version. No other coding system was used. The final list of suggested ICD-codes is presented in Table 1. Codes are truncated to the left for diagnoses that include several diagnostic alternatives. For instance, when excluding ALD in the ICD-10 system, all codes starting with “K70” should be excluded. Therefore, we did not present a more detailed level of codes. The table lists possible exposure and outcome diagnoses as well as exclusion criteria, but does not list
| Diagnosis                                                                 | ICD-8          | ICD-9          | ICD-10         | ICD-11 (version 04/19) |
|---------------------------------------------------------------------------|----------------|----------------|----------------|------------------------|
| **Defining NAFLD at baseline**                                            |                |                |                |                        |
| NAFLD, all                                                                | No available code | 571.8          | K76.0          | D892.0, D892.Z, D892.Y |
| NASH                                                                      | No available code | No available code | K75.8         | D892.1                 |
| **Excluding other liver diseases at/before baseline**                     |                |                |                |                        |
| ALD                                                                        | 571,00, 571.01 | 571.0-571.3    | K70            | D894                   |
| Viral hepatitis                                                            | 999.2, 070     | 070            | B16, B17, B18, B19 | 1E50, 1E51, 1E5Z        |
| Autoimmune liver disease (AIH, PBC, PSC)                                  | No available code | 571.6, 571.6   | K83.0A, K83.0F, K74.3, K75.4 | D896                  |
| Hemochromatosis                                                           | 273.2          | 275.0          | E83.1          | 5C64.1                  |
| Wilson’s disease                                                           | 273.3          | 275.1          | E83.0B         | 5C64.0                  |
| Alpha-1-antitrypsin deficiency                                            | No available code | 277.6          | E88.0A, E88.0B | 5C5A                   |
| Budd-Chiari syndrome                                                      | No available code | 453.0          | I82.0, K76.5   | D898.5                  |
| Chronic hepatitis, unspecified                                            | 570            | 571.4          | K73.9, K73.2   | D897.2                  |
| Secondary or unspecified biliary cirrhosis                                | No available code | 571.6          | K74.4, K74.5   | D893.2                  |
| **Excluding alcohol/drug use disorder at/before baseline**               |                |                |                |                        |
| Codes associated with alcohol use disorder                                | 303            | 303, 305.0     | F10            | 6C40                    |
| Codes associated with somatic consequences of alcohol (except ALD)       | 291, 980.00, 980.01, 980.99 | 291, 357.5, 425.5, 535.3, 980.1, 980.9 | E24.4, G62.1, I42.6, K29.2, G31.2, G72.1, K85.2, K86.0, T51.0, T51.9, Y57.3, X65, Z50.2, 271.4, 272.1 | S570.2, S64.0, 8D44.0, 8D44.1, BC43.0, DA42.80, BA03.30, BD44.4, DC31.1, DC32.3, QB95.2, QE10, 6D72.10, D451.50, 6D84.0 |
| Codes associated with drug use disorders except nicotine/caffeine        | No available code | 305.1-9        | F11-F14, F16, F18, F19 | 6C41, 6C47, 6C48-H |
| **Compensated cirrhosis**                                                 |                |                |                |                        |
| Cirrhosis, compensated                                                   | 571.9          | 571.5          | K74.6          | D893.1                  |
| Esophageal varices, not bleeding                                          | No available code | 456.1, 456.21  | I85.9, I98.2   | D42.01, D42.0Z          |
| Gastric varices, not bleeding                                             | No available code | No available code | I86.4        | D44.0                   |
| **Decompensated cirrhosis**                                              |                |                |                |                        |
| Esophageal varices, bleeding                                              | 456.0          | 456.0, 456.20  | I85.0, I98.3   | D42.00                  |
| Ascites                                                                   | 785.3          | 789.5          | R18            | ME04                    |
| HE                                                                        | No available code | 572.2          | Code for cirrhosis + prescription for lactulose/rifaximin | D899.5                 |
| Hepatorenal syndrome                                                      | No available code | 572.4          | K76.7          | D899.2                  |
| Portal hypertension                                                       | 571.9          | 572.3          | K76.6          | D898.7                  |
| **Liver transplantation**                                                 |                |                |                |                        |
| LT status                                                                 | No available code | V427           | Z94.4          | Q63.3                   |
| **Liver cancer outcomes**                                                |                |                |                |                        |
| HCC                                                                       | 155.01         | 155.0          | C22.0          | 2C12.0                  |
| Liver cancer, unspecified                                                 | No available code | 155.2          | C22.9          | 2C12.2                  |
| **“Unspecific” codes that might be relevant for some studies**            |                |                |                |                        |
| Chronic or unspecified liver failure                                      | 573            | 572.8          | K72.1, K72.9   | D899.7, D899.8          |
| Acute or subacute liver failure                                           | 570            | 570            | K72.0          | D891                    |
| Portal vein thrombosis                                                    | No available code | No available code | I81.9, K75.1  | D898.3                  |
| Hepatic fibrosis or sclerosis or fibrosis with sclerosis                  | No available code | 571.9          | K74.0, K74.1, K74.2 | D893.0                |

Abbreviations: AIH, autoimmune hepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.
an order of how to use these, given that the usage of
codes should be tailored to specific research questions
and data availability across cohorts. All collaborators
agreed on the final set of codes.

After two rounds of revision, a >67% consensus was
established for all 14 recommendations considered
in the final version of the survey, with 6 of 14 ques-
tions having a >90% agreement. The recommenda-
tions and percentage of collaborators that agreed with
each statement are listed below. Replies to the first
round of the survey are presented in the Supporting
Information Appendix (eTable S1). Some questions
from the first round of the survey were redundant and
some were rephrased or added after suggestions from
 collaborators.

**GENERAL RECOMMENDATIONS**

1. Ideally, specific validation studies should be per-
formed for diagnostic codes across different set-
tings. Preferably, validation studies should obtain
random patient charts with the diagnostic code in
question, and the gold standard should be defined
as a prespecified set of criteria to calculate positive
predictive values (PPVs; e.g., histological or radio-
logical signs of cirrhosis for code K74.6 [cirrhosis
of unspecified origin]). It is particularly import-
ant to validate codes representative of NAFLD/
NASH. (100% agreement)

2. The order of coding in administrative databases
should be actively considered. Many systems use
primary and contributing diagnoses. A primary
diagnosis usually defines the main event of a
hospitalization, with contributing diagnoses that
might or might not be associated with that event.
Coding for cirrhosis can thus be a primary diagno-
sis whereas a contributing diagnosis can be made
for the etiological disease, such as NAFLD. For
many research questions, primary codes could be
sufficient, but when a more granular level of data
is required, it could be more appropriate to use
combinations of primary and contributing causes,
depending on the research question. For some re-
search questions, only using primary coding could
lead to a study unable to consider different causes
of cirrhosis. (68% agreement)

3. Where available, the setting of the diagnosis can
be used to enhance its validity. For example, a code
for cirrhosis might have a higher validity when
diagnosed in a hepatology clinic versus a primary
care center. (18) (67% agreement)

**DEFINING NAFLD/NASH**

1. Misclassification of other liver diseases can be
common in NAFLD, perhaps most commonly oc-
curring with ALD. For studies that examine the
risk of “pure” NAFLD, exclusion of concurrent
liver diseases should be made using diagnosis codes
given before or concurrently with the diagnosis of
NAFLD. Suggested codes for these diseases are
listed in Table 1. Concurrent liver diseases can also
be diagnosed after a diagnosis of NAFLD, but the
methodology for how to treat these depends on
the research question. (74% agreement)

2. To define NASH, the ICD-10 code K75.8 should
be primarily used. However, local/national prac-
tices should be considered. (82% agreement)

3. Defining and separating NASH from simple stea-
tosis can be difficult, and in general EHR-based
research cannot accurately distinguish NASH
from simple steatosis in the absence of biopsy.
Studies that try to accomplish a high specificity of
correctly identifying NASH could use procedure
coding for liver biopsy to increase specificity of the
NASH diagnosis (i.e., a code of K75.8 plus a code
for liver biopsy). In general, this approach should
also report the time interval between biopsy and
NASH diagnosis to increase transparency. (84%
agreement)

**ASCERTAINING PROGRESSION TO
CIRRHOSIS**

1. When ascertaining progression to cirrhosis, spe-
cific coding for cirrhosis needs to be present to
define progression to cirrhosis. Studies should not
count events, such as hospitalizations, where only
coding for NAFLD/NASH is available, as defin-
ing cirrhosis. (100% agreement)

2. Liver disease outcomes are generally rare in most
populations. A composite outcome, including di-
agnoses related to complications of cirrhosis of
high validity, should generally be applied when
ascertaining outcomes associated with cirrhosis.
Our recommendations for these are specified in
Table 1. For instance, for a person where bleed-
ing esophageal varices are found but there is no
diagnosis of cirrhosis or competing cause such as PVT, they should be counted as having cirrhosis. However, the etiology of cirrhosis should be individually determined. Special considerations are also needed for potential liver-related outcomes that could be caused by other underlying conditions (see statement #11). (94% agreement)

ASPECTS ON CODING FOR CIRRHOSIS

1. Specific coding for NAFLD/NASH in patients with cirrhosis might be missing in some registries/databases. Coding for metabolic syndrome components (diabetes type 2, obesity, hypertension, or hyperlipidemia) at or before the cirrhosis event may be considered to improve sensitivity of capturing NAFLD-related cirrhosis outcomes. Such an approach should also be validated in accordance with statement #1. (79% agreement)

2. For HCC outcomes, the specific code for HCC should be used (ICD-10: C22.0), given that coding for “Liver cancer, unspecified” (ICD-10: C22.9) is likely to have a low specificity for HCC. However, the C22.9 code can be used for sensitivity analyses. (94% agreement)

3. Ascites may be caused by cirrhosis, but there are other causes of nonhepatic ascites such as heart failure or malignancy. In studies of patients with known chronic liver disease status (such as NAFLD, ALD, or cirrhosis), ascites can be used as a liver-related outcome, but in general in population cohorts, ascites should be combined with coding for chronic liver disease to achieve an acceptable specificity. (94% agreement)

4. HE does not have a specific code in ICD-10. To define HE, coding for compensated or decompensated cirrhosis can be combined with coding for prescriptions (such as Anatomical Therapeutic Chemical Classification System codes) of lactulose or rifaximin to increase specificity, in settings where such data are available. For instance, a person with a diagnosis of cirrhosis and a prescription of rifaximin can be considered as having HE. (78% agreement)

5. Coding for liver failure might represent cirrhosis, but there are alternate causes and specificity might be low. Unless validation studies are performed in the system of the study setting, chronic liver failure codes (ICD-10: K72.1, K72.9) should only be considered as defining cirrhosis in sensitivity analyses, and acute liver failure codes should not be used when defining cirrhosis. (95% agreement)

6. Procedure codes can in general be used to ascertain outcomes related to cirrhosis and can be used alone even if specific coding for cirrhosis is lacking. For example, a case with coding for banding of bleeding esophageal varices, but no formal coding for varices per se, can help define decompensated cirrhosis. However, in contrast to the diagnostic ICD systems, there are a multitude of different procedure code systems and a list of procedure codes should be defined by the individual research group depending on the setting. (83% agreement)

Procedure codes that could be interesting would depend on the research question. LT is a commonly used outcome that can be studied in itself or as part of a composite outcome. There are certain ICD codes for the presence of an LT (ICD-10: Z94.4), but procedure coding could also be added to define LT and would be better to define the date of the transplantation.

Procedures that are strongly associated with cirrhosis include banding or ligation of esophageal or gastric varices, paracentesis, and TIPS placement.

Discussion

We present a comprehensive list of ICD codes that can serve as guidance for future studies of NAFLD when using EHR data, for instance how to define NAFLD in study cohorts and how to ascertain progression to cirrhosis. This guidance could be used both when using administrative and clinical databases, as well as upcoming phase 4 studies in the NAFLD/NASH field. Harmonization of definitions will make it easier to compare and contrast study results from different cohorts, leading to an improved understanding of the consequences of NAFLD. These recommendations could also provide guidance for clinicians or administrators responsible for coding disease status in patients with NAFLD.

We also give guidance on some key methodological questions in the field.

However, no guidance can cover all possible research questions or study settings, which is why these recommendations should not be a mandate, but
rather a suggestion of relevant codes that can be used to define exposure or outcome variables. Some registries/databases might contain more detailed data, such as laboratory data or results from radiology, which allow for more granular definitions than made here. Moreover, some regions may have different coding systems or coding practices so that our recommendations could be irrelevant.

This should not be seen as a complete guide on how to perform research in this field. Different research questions and study settings will require distinct strategies. For instance, examining liver-related outcomes in an EHR-derived general population with unknown NAFLD status is different than examining liver-related endpoints in clinical cohorts with known NAFLD status. EHR-derived, population-based cohorts often have a low risk for cirrhosis and have the possibility of having liver diseases other than NAFLD, whereas the definition of outcomes could be made narrower by combining codes through prespecified algorithms. An example of this is requiring a code for chronic liver disease when ascites is diagnosed, given that there are other causes of ascites apart from cirrhosis, thus risking false-positive findings. This can be compared to EHR-based follow-up studies of persons with known NAFLD, where it is less likely that ascites would be related to competing causes. Again, definitions should be tailored to the specific research question. Also, liver-related outcomes are relatively rare in a general population, and consideration of examining more common causes of mortality should be actively considered, depending on the research question.

When assessing the overall impact of NAFLD on clinical liver outcomes in the general population, there is a need to recognize that NAFLD often coexists with ALD, and that metabolic risk factors and alcohol use have bidirectional interaction effects on liver disease with in general higher risk for liver-related outcomes in persons with mixed etiologies. In such research settings, the exclusion of competing and coexistent causes for liver disease may lead to lower risk estimates associated with NAFLD. For instance, excluding diagnoses of alcohol-related outcomes (ICD-10: K70.3) will reduce the sensitivity of the impact of NAFLD in persons with coexisting NAFLD and ALD, and thought needs to be given to the possible coexistence of NAFLD and ALD when designing EHR-based studies depending on the research question. This is true for most uses of algorithms using ICD coding. The requirement of multiple codes to enhance specificity will almost always lead to a lower sensitivity and underappreciation of the prevalence of the target diagnosis, which should be considered depending on the research question(s).

It should also be acknowledged that NAFLD is severely undercoded in the general population, although there are methods to enhance detection of NAFLD in databases with a high level of details. Consequently, there is often misclassification bias (attributable to inaccurate coding of subjects in “control” groups), resulting in attenuation of any association toward the null, but also selection bias (cases diagnosed with NAFLD might be the more severe cases, resulting in inflated risk estimates).

Preferably, validation studies of codes or algorithms used to increase the PPV of the target diagnosis should be undertaken before starting an EHR-based study, if possible. Examples of these are provided in previous works. Results of earlier validation studies in hepatology in general suggest that although some diagnoses have a high PPV, there are several nonspecific diagnoses where considerations need to be made. An example is ascites, which can be found in persons without cirrhosis, but combining coding for ascites with coding for cirrhosis leads to acceptable PPVs. Another example is HE, where combining drug prescription coding with cirrhosis increases PPVs to acceptable levels. One must also take into account the setting where the diagnosis is made. For instance, a diagnosis of “chronic liver failure” made by a hepatologist might have higher validity when compared to the same diagnosis made in a general hospital.

**AREAS OF CONTROVERSY AND CONSIDERATIONS FOR FUTURE RESEARCH**

Statements where <90% of collaborators agreed can be considered to be somewhat controversial and may represent areas for future studies. For instance, how to best classify disease etiology in persons in a general population setting who develop cirrhosis can be difficult when there is no etiological coding, meaning that differentiating between, for example, ALD and NAFLD as the cause of cirrhosis can be difficult.

Similarly, how to deal with study subjects with multiple etiological codes (e.g., NAFLD and ALD)
at different time points during study follow-up was considered to be too nuanced and study dependent to make a general recommendation and could be a topic for a future study. Given that NAFLD is severely undercoded, future studies should also consider how to best use available ICD coding, such as combinations of metabolic syndrome components, to achieve an acceptable accuracy for estimation of NAFLD in the general population.

Additionally, full consensus could not be achieved on how to best classify HE in the absence of a specific ICD code. Some collaborators thought that defining HE by codes for cirrhosis and a prescription code for lactulose risked misclassifying persons where lactulose might be used for primary prevention.

Finally, we chose to limit our discussion to liver-related outcomes, and how to best examine the role of NAFLD in cardiovascular disease using EHR data remains an open question.

**Conclusion**

We defined a list of ICD codes that can be considered by investigators examining NAFLD in EHR-based research and reached consensus statements addressing several methodological questions. This guidance is intended to streamline future studies in this field, leading to increased generalizability of study results, with the aim to improve our understanding of NAFLD prognosis pertaining to liver-related outcomes.

**Author Contributions:** Study conception and design: H.H., F.A. Acquisition of data: All. Statistical analysis: N/A. Analysis and interpretation of data: All. Drafting of manuscript: H.H. Critical revision: All.

**Guarantor of Article:** H.H.: All authors approved the final version of the article, including the authorship list.

**Writing Assistance:** None.

**REFERENCES**

1) Sørensen HT, Lash TL, Rothman KJ. Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. *Hepatology* 2006;44:1075-1082.

2) Ekstedt M, Hagstrom H, Nasr P, Fredriksson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. *Hepatology* 2015;61:1547-1554.

3) Feldstein AE, Charatcharoenwitthaya P, Treeratsertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. *Gut* 2009;58:1538-1544.

4) Hagstrom H, Nasr P, Ekstedt M, Hammar U, Stal P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. *J Hepatol* 2017;67:1265-1273.

5) Jepsen P, Vilstrup H, Mellemkjaer L, Thulstrup AM, Olsen JH, Baron JA, et al. Prognosis of patients with a diagnosis of fatty liver—a registry-based cohort study. *Hepatogastroenterology* 2003;50:2101-2104.

6) Kaps L, Labenz C, Galle PR, Weinnmann-Menke J, Kostev K, Schattenberg JM. Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. *United European Gastroenterol J* 2020;8:942-948.

7) Wild SH, Walker JJ, McAllister DA, Colhoun HM, Farran B, et al. Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or non-alcoholic fatty liver disease hospital admission. *Diabetes Care* 2018;41:341-347.

8) European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). **EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.** *J Hepatol* 2016;64:1388-1402.

9) Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guidance from the American Association for the Study of Liver Diseases. *Hepatology* 2018;67:328-357.

10) Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. *BMJ* 2019;367:l5367.

11) Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. *BMC Med* 2019;17:95.

12) Bengtsson B, Stal P, Wahlin S, Bjorkstrom NK, Hagstrom H. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. *Liver Int* 2019;39:1098-1108.

13) Allen AM, Therneau TM, Larson JJ, Coward A, Somers VK, Kamath PS. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study. *Hepatology* 2018;67:1726-1736.

14) Allen AM, Van Houten HK, Sangaralingham LR, Talwalkar JA, McCoy RG. Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large U.S. claims database. *Hepatology* 2018;68:2230-2238.

15) Åberg F, Puukka P, Salomaa V, Männistö S, Lundqvist A, Valsta L, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. *BMC Med* 2019;17:95.

16) Unalp-Arild A, Ruhl CE. Patatin-like phospholipase domain-containing protein 3 I148M and liver fat and fibrosis scores predict liver disease mortality in the U.S. population. *Hepatology* 2020;71:820-834.

17) Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanavatpakul M, Richardson PA, et al. Risk of Hepatocellular cancer in patients with non-alcoholic fatty liver disease. *Gastroenterology* 2018;155:1828-1837.e2.
18) Bengtsson B, Askling J, Ludvigsson JF, Hagström H. Validity of administrative codes associated with cirrhosis in Sweden. Scand J Gastroenterol 2020;55:1205-1210.

19) Tapper EB, Korovaichuk S, Baki J, Williams S, Nikirk S, Waljee AK, et al. Identifying patients with hepatic encephalopathy using administrative data in the ICD-10 era. Clin Gastroenterol Hepatol 2019 Dec 27. https://doi.org/10.1016/j.cgh.2019.12.017. [Epub ahead of print]

20) Lapointe-Shaw L, Georgie F, Carlone D, Cerocchi O, Chung H, Dewir Y, et al. Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: a validation study. PLoS One 2018;13:e0201120.

21) Goldberg D, Lewis J, Halpern S, Weiner M, Lo Re V III. Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. Pharmacoepidemiol Drug Saf 2012;21:765-769.

22) Re VI, Lim JK, Goetz MB, Tate J, Bathulapalli H, Klein MB, et al. Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf 2011;20:689-699.

23) Kaplan DE, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, et al. Development and performance of an algorithm to estimate the Child-Turcotte-Pugh score from a national electronic healthcare database. Clin Gastroenterol Hepatol 2015;13:2333-2341.e1-6.

24) Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess 1998;2:i-v,1-88.

25) Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol 2014;67:401-409.

26) Hagström H, Talbäck M, Andreason A, Wallius G, Hammar N. Ability of noninvasive scoring systems to identify individuals in the population at risk for severe liver disease. Gastroenterology 2020;158:200-214.

27) Hagström H, Tynelius P, Rasmussen F. High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men. Gut 2018;67:1536-1542.

28) Åberg F, Färkkilä M. Drinking and obesity: alcoholic liver disease/nonalcoholic fatty liver disease interactions. Semin Liver Dis 2020;40:154-162.

29) Liu B, Balkwill A, Reeves G, Beral V; Million Women Study Collaborators. Body mass index and risk of liver cirrhosis in middle-aged UK women: prospective study. BMJ 2010;340:c912.

30) Blais P, Husain N, Kramer JR, Kowalkowski M, El-Serag H, Kanwal F. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroenterol 2015;110:10-14.

31) Alexander M, Loomis AK, Fairburn-Beech J, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, et al. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med 2018;16:130.

32) Husain N, Blais P, Kramer J, Kowalkowski M, Richardson P, El-Serag HB, et al. Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data. Aliment Pharmacol Ther 2014;40:949-954.

33) Corey KE, Kartoun U, Zheng H, Shaw SY. Development and validation of an algorithm to identify nonalcoholic fatty liver disease in the electronic medical record. Dig Dis Sci 2016;61:913-919.

34) Driver RJ, Balachandrakumar V, Burton A, Shearer J, Downing A, Cross T, et al. Validation of an algorithm using inpatient electronic health records to determine the presence and severity of cirrhosis in patients with hepatocellular carcinoma in England: an observational study. BMJ Open 2019;9:e028571.

Supporting Information

Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.31726/suppinfo.